Literature DB >> 15129119

Postirradiation vertigo in nasopharyngeal carcinoma survivors.

Yi-Ho Young1, Jenq-Yuh Ko, Tzung-Shiahn Sheen.   

Abstract

OBJECTIVE: Vertigo rarely manifested as an initial symptom of nasopharyngeal carcinoma or an early symptom after irradiation; however, increasing numbers of long-term nasopharyngeal carcinoma survivors experienced it. The purpose of this study was to investigate the causes of vertigo in irradiated nasopharyngeal carcinoma survivors.
SETTING: University hospital. PATIENTS: From January 1992 to December 2001, a total of 113 nasopharyngeal carcinoma patients (67 men and 46 women) with postirradiation vertigo consecutively visited our vertigo clinic. The mean interval from completion of irradiation to the occurrence of vertigo was 10 years. Each patient underwent otoscopic examination and a battery of audiovestibular function tests. Then, correlation between the vertigo and the radiation effect was explored.
RESULTS: Postirradiation vertigo was mainly attributable to peripheral labyrinthine disorder (69%), followed by central vestibular lesions (31%). The vertiginous and associated symptoms including severity, nausea/vomiting, oscillopsia, or imbalance in cases of peripheral labyrinthine disorder were milder than those in central vestibular lesion. Meanwhile, the former had less life impact and better response to therapy compared with the latter. The mean radiation dosage in both groups was 73 +/- 6 Gy and 74 +/- 5 Gy, respectively, without a significant difference. Of these 113 patients, 85 patients (75%) had radiation otitis media in one or both ears, and 28 patients disclosed bilateral intact eardrums. The prevalence of radiation otitis media in patients with postirradiated vertigo was 53% versus 73% for those with radiation dosage less than or more than 71 Gy, respectively, exhibiting a significant difference. However, the prevalence of radiation otitis media is unrelated to radiation interval. In comparison with absent caloric responses in radiation otitis media ears, 32% versus 57% in those of less than or more than 71 Gy, respectively, indicates a significant difference.
CONCLUSIONS: Vertigo is a late complication in irradiated nasopharyngeal carcinoma survivors, which is mainly caused by the sequela of radiation otitis media. Because the latter is correlated with the radiation dosage, 70 Gy is recommended as the maximum dosage for nasopharyngeal carcinoma. Eradicating radiation otitis media in nasopharyngeal carcinoma survivors may subsequently prevent the postirradiation vertigo.

Entities:  

Mesh:

Year:  2004        PMID: 15129119     DOI: 10.1097/00129492-200405000-00027

Source DB:  PubMed          Journal:  Otol Neurotol        ISSN: 1531-7129            Impact factor:   2.311


  5 in total

1.  Psychological disorders, cognitive dysfunction and quality of life in nasopharyngeal carcinoma patients with radiation-induced brain injury.

Authors:  Yamei Tang; Donghua Luo; Xiaoming Rong; Xiaolei Shi; Ying Peng
Journal:  PLoS One       Date:  2012-06-11       Impact factor: 3.240

2.  Balance Performance in Irradiated Survivors of Nasopharyngeal Cancer with and without Tai Chi Qigong Training.

Authors:  Shirley S M Fong; Louisa M Y Chung; William W N Tsang; Joyce C Y Leung; Caroline Y C Charm; W S Luk; Lina P Y Chow; Shamay S M Ng
Journal:  Evid Based Complement Alternat Med       Date:  2014-09-11       Impact factor: 2.629

3.  Effect of Hydrogen Inhalation Therapy on Hearing Loss of Patients With Nasopharyngeal Carcinoma After Radiotherapy.

Authors:  Xiaofeng Kong; Tianyu Lu; You-Yong Lu; Zhinan Yin; Kecheng Xu
Journal:  Front Med (Lausanne)       Date:  2022-03-31

4.  Benign paroxysmal positional vertigo in irradiated nasopharyngeal carcinoma survivors.

Authors:  Shaoyan Feng; Yunping Fan; Liqing Guo; Zibin Liang; Jiaoping Mi
Journal:  ISRN Otolaryngol       Date:  2013-10-24

5.  Correlation between delivered radiation doses to the brainstem or vestibular organ and nausea & vomiting toxicity in patients with head and neck cancers - an observational clinical trial.

Authors:  Kilian Schiller; Hanno Martin Specht; Bernhard Haller; Daniela Hallqvist; Michal Devecka; Aaron Becker von Rose; Stephanie Elisabeth Combs; Steffi Pigorsch
Journal:  Radiat Oncol       Date:  2017-07-04       Impact factor: 3.481

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.